Nuvama Institutional Equities has initiated coverage on Laurus Labs with a ‘Buy’ rating and a target price of Rs 2,520, implying a 24% upside from the current market price. The brokerage expects the drugmaker’s shift from its traditional anti-retroviral (ARV) business towards contract development and manufacturing (CDMO) to drive its next phase of growth.
Nuvama Institutional Equities has initiated coverage on Laurus Labs with a ‘Buy’ rating and a target price of Rs 2,520, implying a 24% upside from the current market price. The brokerage expects the drugmaker’s shift from its traditional anti-retroviral (ARV) business towards contract development and manufacturing (CDMO) to drive its next phase of growth.
<iframe src="https://hindustansphere.com/embed/cluster/5f141ee87ade93956c6e0a12734b0037088d4bfb" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside"></iframe>
